Profisil Free
Kettenbach GmbH & Co. KG · Decision date Sep 3, 2026
What did the FDA decide?
FDA recorded a substantial-equivalence decision (SESE) for Profisil Free, a cavity varnish from Kettenbach GmbH & Co. KG, dated September 3, 2026, under 21 CFR 872.3260, Class II, product code LBH, in the Dental specialty. The submission, K262243, was dated and received July 1, 2026. The device is described as a fluoride-free varnish intended to produce mechanical occlusion of dentinal tubules in treating tooth hypersensitivity, supplied in single-dose 0.5 mL blisters with an applicator brush.
The listed predicate is ReminGel (Inter-Med, Inc. / Vista Apex), K241489. The summary states the intended purpose, indication, patient population, mechanism of action and principle of operation are the same in substance, while the formulation base and delivery system differ; it concludes the packaging difference does not affect the equivalence determination. Biocompatibility testing under cited ISO 10993 parts is reported. The provided excerpts do not include the full contraindications text, shelf-life data or the complete performance results.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Sep 3, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262243
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Kettenbach GmbH & Co. KG
- Product code
- LBH
- Decision code
- SESE
- Decision date
- Sep 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Varnish, Cavity.
- Applicant
- Kettenbach GmbH & Co. KG
- Product code
- LBH
- FDA device class
- 2
FDA decision timeline
K262243 received
Application receipt date recorded by FDA.
K262243 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LBH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| The Belport Company Inc., DBA Gingi-Pak | 510(k) clearance | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kettenbach GmbH & Co. KG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Eschenburg
Sources and methodology
- Original FDA record: K262243
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records